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ABSTRACT
Introduction: The prevalence of diabetes mellitus (DM) in Malaysia is drastically increasing. Subjects with DM are 
more likely to have deranged liver function tests (LFT). This study aimed to determine the prevalence of abnormal liv-
er enzymes [(alanine aminotransferase (ALT) and alkaline phosphatase (ALP)] and its associated factors among type 
2 DM (T2DM) subjects visiting a referral diabetic clinic in a tertiary government hospital. Methods: This retrospec-
tive, cross-sectional study included electronic data of 300 T2DM subjects ≥18 years old in the outpatient specialist 
clinic from January 2011 to December 2014. Statistical analysis was performed using SPSS version 22. Results: The 
study population at large included Malays, of age >60 years with comparable gender percentage. Most subjects had 
long-standing DM, poor glycaemic control and were on treatment. The prevalence of abnormal ALT and ALP was 
27.3% and 13%; with 90.2% and 97.4% having mild ALT and ALP elevations, respectively. Significant associations 
noted for age, body mass index (BMI) and duration of T2DM for ALT whereas for ALP, anti-diabetic medication was 
significant between groups of normal and abnormal levels. Deranged liver enzymes were associated significantly 
with dyslipidaemia. Conclusion: Our study on the crude prevalence of raised liver enzymes may help identify T2DM
patients at increased risk of non-alcoholic fatty liver disease (NAFLD). Modification of metabolic risk factors, such 
as weight loss, control of dyslipidaemia rather than just tighter glycaemic control should be emphasised to reduce 
morbidity and mortality. Liver enzymes remain a simple and non- invasive marker of liver pathology in daily medical 
practice. 
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INTRODUCTION
In Malaysia, the overall prevalence of diabetes mellitus 
(DM) among adult population of more than 18 years old 
is 17.5% (1). By 2030, WHO has predicted the number 
of people with DM in Malaysia would be 2.48 million 
(2). Type 2 DM (T2DM) is often associated with liver 
function abnormalities covering the entire spectrum 
from asymptomatic raised liver enzymes to cirrhosis (3). 
Liver plays an essential part in glucose homeostasis (4). 
The link between T2DM and Non-Alcoholic Fatty Liver 
Disease (NAFLD) is insulin resistance, the underlying 
pathophysiology in both disease processes (5). NAFLD 
patients with T2DM are at increased risk of non-alcoholic 
steatohepatitis (NASH), fibrosis, and cirrhosis compared 
with patients without T2DM (6). In the insulin-resistant 
state, the excess in free fatty acids are directly toxic to 
liver cells. Alleged mechanisms include disruption of 
cell membrane, dysfunction of the mitochondria, toxins 
and disturbance in metabolic processes. Other potential 
explanations include reactive lipid peroxidation and 
peroxisomal beta-oxidation causing oxidative stress and 
increase in proinflammatory cytokines (4). 
Liver function tests (LFTs) are used routinely for screening, 
support diagnosis, monitor progression, severity and 
treatment of liver disease as well as the side-effects of 
hepatotoxic medications (4). Derangement in LFT are 
found to be higher in subjects with T2DM than non-
diabetics (3). In Malaysia, LFT profile in the government 
hospital setting comprises of the following parameters: 
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total protein (TP), albumin (ALB), total bilirubin 
(TBIL), alanine aminotransferase (ALT) and alkaline 
phosphatase (ALP). Gamma glutamyl transferase (GGT) 
and aspartate aminotransferase (AST) are not routinely 
done unless requested by the clinician. Hence, liver 
enzymes assessed in this study were ALT and ALP only.
Although ALT is considered a suboptimal biomarker 
for liver pathology, its sensitivity in predicting steatosis, 
a surrogate marker for early NAFLD is 62.5%. This is 
significantly high compared with GGT and AST at 20% 
and 18%, respectively (6). Significant differences in ALT 
levels were found between subjects with mild NAFLD 
and those without NAFLD, and between those with 
severe and mild NAFLD, suggesting that serum ALT 
levels might offer the capacity to discriminate among 
different degrees of liver fat content (7). 
ALP, predominantly in bone and liver, has been generally 
seen in patients with metabolic bone disorders and/or 
diseases with hyperfiltration of the kidney. Both these 
conditions are associated with T2DM (8).  Kocabay et 
al. found that ALP was significantly increased in patients 
with liver fibrosis than patients without it, concluding 
that ALP may be a potential risk factor of liver fibrosis in 
T2DM patients with NASH (9).
An additional contribution to LFT abnormalities in 
these T2DM patients managed in a tertiary setting 
may be medications such as anti-diabetic medications 
and statins. Oral hypoglycaemic drugs (OHA) such as 
sulphonylureas, biguanide, meglitinides, pioglitazone 
and α-glucosidase inhibitors cause hepatotoxicity. 
Previous meta-analyses summarised the effects of 
statin therapy on liver injury from 13 RCTs involving 
49,275 participants, indicating low-to-moderate doses 
of pravastatin, lovastatin, and simvastatin were not 
significantly associated with liver abnormalities (10). 
However, the meta-analysis by Liang X et al, based on 
74,078 participants from 16 studies illustrated that the 
risk of liver injury was increased by 22% among patients 
on statin therapy. Subgroup analysis showed fluvastatin 
increased liver injury significantly rather than other types 
of statins (11). However, elevation of transaminases 
within three times the upper limit of normal is not a 
contraindication for starting OHA or statins (4, 12).  
Previous studies in different geographical locations have 
suggested varying prevalence of deranged liver enzymes 
that are markers of asymptomatic NAFLD in T2DM (6, 
13-22). There are limited assessments in the local setting. 
Thus, in the present pilot study, we aimed to examine the 
prevalence of elevated liver enzymes (ALT and ALP) and 
its associated factors in T2DM in a selected multiethnic 
Malaysian population visiting a referral diabetic clinic in 
Hospital Serdang, a tertiary government hospital.
 
MATERIALS AND METHODS
Study design 
This retrospective, cross-sectional study included data 
of 300 T2DM subjects ≥ 18 years old who were seen in 
the outpatient diabetic clinic at Hospital Serdang from 
January 2011 to December 2014. Diagnosis of T2DM in 
the Ministry of Health hospitals was made based on the 
4th edition of the Malaysian Clinical Practice Guidelines 
on Management of Type 2 Diabetes Mellitus (23). 
Sample size calculation for hypothesis testing purpose 
was done using the prevalence of increased ALT in 
obese (P1=0.192) and non-obese (P2=0.110) T2DM 
patients (24), giving a sample size of 298 patients. 
Exclusion criteria included type 1 diabetes mellitus 
subjects, pregnant subjects, subjects with history of 
alcohol abuse, subjects on hepatotoxic drugs, subjects 
seropositive for HbsAg, HCV Ab, HIV infection and 
those who had autoimmune liver disease, cirrhosis 
and subjects with cor pulmonale or congestive cardiac 
failure and having proteinuria at least 1+ (qualitative) on 
urine dipstick method. 
Data collection
Electronic records of the initial visit to the clinic were 
extracted. Retrospective laboratory data included initial 
fasting blood glucose (FBG), glycated haemogobin 
(HbA1c), fasting serum lipid [FSL: total cholesterol (TC), 
triglyceride (TG), low dense lipoprotein cholesterol 
(LDL) and high dense lipoprotein cholesterol (HDL)] and 
LFT (TP, ALB, TBIL, ALT and ALP) taken on the same 
day. Demographic factors [gender, age, ethnicity, body 
mass index (BMI)] and clinical findings [medications, 
duration of T2DM] were also recorded from electronic 
data. 
Biochemical analysis
FBG, FSL and LFT were analysed on the automated 
Synchron LX20 Pro chemistry analyser (Beckman 
Coulter, Massachusetts, USA) whereas plasma 
HbA1c used ion-exchange high performance liquid 
chromatography (HPLC) method on the D10 BIORAD 
system (Biorad Laboratories, Hercules, California, USA).
Abnormal ALT and ALP levels were defined as enzyme 
activity > 30 U/L and >150 U/L [upper limit of normal 
(ULN)], respectively as per the reference interval used by 
the hospital’s laboratory on the Synchron LX20 Pro. The 
magnitude of liver enzyme alterations were categorised 
as mild (< 5x ULN), moderate (5x - 10x ULN) and 
marked (> 10x ULN) [25].
Statistical analysis
Statistical analysis was done using IBM SPSS Statistics 
version 22.0 (IBM, Armonk, NY, USA). Mann Whitney, 
Kruskal Wallis and Chi Square tests were used were 
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used to analyse non-Gaussian data. A p-value of ≤ 0.05 
was taken to be statistically significant.
Ethics
The study was approved by both The Medical Research 
and Ethics Committee, Ministry of Health Malaysia (ID: 
NMRR-15-558-25499) and The Ethics Committee for 
Research involving Human Subjects of Universiti Putra 
Malaysia [Ref. no: FPSK (EXP15-MEDIC)U030].
RESULTS
The study population at large included Malays, of age 
more than 60 years with comparable gender percentage. 
Majority had long-standing DM and were on treatment 
with OHA. The rest were either on insulin or both OHA 
and insulin. Median BMI of study population was 26.5 
kg/m2 (Table I). 
Table I: Demographics and clinical characteristics of study popula-
tion (N=300)
Variable n (%)
Gender 
 Male
 Female
Age (years)
< 60 
≥ 60 
Ethnicity 
Malay
Chinese
Indian
BMI 
Obese (BMI > 27.5kg/m2) 
Non obese (BMI ≤27.5)
Missing data
Duration of T2DM 
< 5 years
≥ 5 years 
Missing data
Anti-diabetic medication 
Oral hypoglycemic agent (OHA)
Insulin
OHA & insulin
Statin
Yes                                                                          
 No                                             
155 (51.7)
145 (48.3)
149 (49.7)
151 (50.3)
168 (56.0)
72 (24.0)
60 (20.0)
59 (19.7)
83 (27.7)
158 (52.7)
53 (17.7)
122 (40.7)
125 (41.6)
161 (53.7)
74 (24.7)
65 (21.7)
174 (58.0)
126 (42.0)
Table II shows the laboratory parameters of the study 
population. Median for all analytes were within the 
reference range except for FBG and HbA1c, which were 
raised and HDL, which was just below the lower limit 
of normal. The prevalence of abnormal ALT and ALP in 
this study was 27.3% and 13%; with 90.2% and 97.4% 
having mild ALT and ALP elevations, respectively (Table 
III).
Table IV compares associated factors of T2DM subjects 
with and without abnormal ALT. Significant associations 
were for age, BMI and duration of T2DM. Subjects with 
abnormal ALT had a significantly higher TG, TBIL, TP 
and ALP and a lower HDL level compared to the normal 
ALT group.
Table II: Laboratory parameters of study population
Parameter n** Median (IQR) Min – Max Reference 
range*
FBG (mmol/L) 232 8.05 (6.85) 1.4 – 19.95 3.89 – 5.8
HbA1c (%) 192 8.00 (3.60) 5.0 – 18.5 < 6.5
TC (mmol/L) 242 4.73 (1.85) 2.42 – 8.38 ≤ 5.17
TG (mmol/L) 242 1.65 (1.04) 0.45 – 5.30 ≤ 1.70
LDL-C (mmol/L) 242 2.81 (1.52) 0.56 – 5.72 ≤ 3.37
HDL-C (mmol/L) 242 1.02 (0.39) 0.13 – 2.10 ≥ 1.04 
Total protein (U/L) 300 73.0 (8.00) 39.00 – 89.0 64 – 83
ALB (g/L) 300 36.0 (8.00) 29.0 – 61.0 35 – 50
TBIL (µmol/L) 300 10.35 (7.75) 1.11 – 165.1 3.4 – 20.5
ALT (U/L) 300 19.0 (15.00) 6.0 – 374.0 3.0 – 30.0
ALP (U/L) 295 83.0 (45.50) 21.0 – 836.0 40.0 – 150.0
*  based on Hospital Serdang LIS 2015.
** the number of subjects (n) differed for each analyte due to unrecorded data (missing data)
Table III: Classification of liver enzymes (ALT &ALP) based on magni-
tude of liver enzyme alteration
ALT
(3 – 30) U/L
N = 82
n (%)
ALP
(40 – 150) U/L
N = 39
n (%)
Mild (<5x ULN) 74 (90.2) Mild (<5x ULN)  38 (97.4)
Moderate (5x-10x 
ULN) 
4 (4.9) Moderate (5x-10x 
ULN)
1 (2.6)
Severe (>10x 
ULN)
4 (4.9) Severe (>10x ULN) 0 (0.0)
ULN: upper limit of normal
Tables V shows the comparison in associated factors 
between T2DM subjects with and without abnormal 
ALP. Only anti-diabetic medication was significant 
between the two groups. Subjects with abnormal ALP 
had a significantly higher ALT and a lower HDL and ALB 
level compared to the normal ALP group.
DISCUSSION
In this study, a much higher prevalence of increased 
ALT levels (27.3%) in T2DM was found compared to 
India (13, 14), Denmark (6), Myanmar (15), Italy (16), 
UK (17, 18),  Jordan (24) and US (19) with  prevalence 
of 19.8-24.5%, 20%, 18.5%, 16%, 12.1-15.7%, 
10.4% and 7.8%, respectively. On the contrary, 
Bangladesh (20), Pakistan (21) and Nepal (22) reported 
higher prevalence of ALT with 31%, 34.6% and 57%, 
respectively compared to our study. The prevalence 
of increased ALP was 13% in our study, which was 
higher than UK; 10.4% (17) and Nepal; 7% (22) but 
much lower than India with prevalence between 33-
41.2% (13, 14).  The varied prevalence of deranged 
liver enzymes in T2DM among diverse populations may 
be due to the different study methodology and cut-off 
values used for liver enzymes. It may also depend on 
the prevalence of diabetes and its complications in the 
particular population suggesting other associated factors 
and pathophysiological mechanisms of T2DM may be 
contributory.
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Table IV: Demographic factors, clinical findings and laboratory pa-
rameters between T2DM subjects with and without abnormal ALT
Variable
Normal ALT
(ALT 3 – 30 U/L)
n = 218
Abnormal ALT
(ALT > 30 U/L)
n = 82 χ2* p 
value***
n (%) n (%)
Gender 
Male
Female
113
105
(51.8)
(48.2)
42
40
(51.2)
(48.8)
0.009 0. 924
Age (years)
< 60
≥ 60
95
123
(43.6)
(56.4)
54
28
(65.9)
(34.1)
11.827 0.001
Ethnicity 
Malay
Chinese
Indian
BMI****
Obese
Non obese
119
53
46
35
67
(54.6)
(24.3)
(21.1)
(34.3)
(65.7)
49
19
14
24
16
(59.8)
(23.2)
(17.0)
(60.0)
(40.0)
0.800
11.689
0.670
0.001
Duration T2DM**** 
(years) 
<5 
≥5 
35
95
(26.9)
(73.1)
18
27
(40.0)
(60.0)
5.837 0.016
Anti-diabetic 
medication
OHA
Insulin
OHA & insulin
Statin
Yes                    
No
           
114
       59
45
   
        
120 
98
(52.3)
(27.1)
(20.6)
 (55.0)
 (45.0)
47
15
20
54
28
(57.3)
(18.3)
(24.4)
 (65.9)
 (34.1)
2.525
2.856
0.283
0.091
Laboratory 
parameters
Median (IQR) Median (IQR) z** p 
value***
FBG (mmol/L)  7.84 (6.82) 8.81 (7.37) -1.264 0.206
HbA1c (%)  7.95 (3.65) 8.20 (3.45) -0.396 0.692
TC (mmol/L) 4.76 (1.74)     4.6 (2.64) -1.28 0.206
TG (mmol/L)    1.56 (0.92)  1.93 (0.86) -3.368 0.001
LDL (mmol/L)   2.89 (1.46) 2.66 (2.06) -1.413 0.158
HDL mmol/L)  1.06 (0.43)   0.93 (0.31) -4.466 < 0.001
Total protein (U/L)  73.0 (7.75)      75.0 (9.00) -2.078 0.038
ALB (g/L)  35.0 (8.00) 36.0 (8.00) -1.943 0.052
TBIL (µmol/L) 9.80 (6.55) 12.75 (10.73) -3.973 < 0.001
ALP (U/L)  80.5 (41.0) 96.5 (47.0) -4.808 < 0.001
*Since n > 20 and there is no expected value less than 5, Pearson Chi-Square is used. 
**Mann Whitney statistical test (z).
***Statistical significance at p < 0.05.  The significant variables are shown in bold. 
****For BMI (normal ALT n=102; abnormal ALT n=40) and duration of T2DM (normal ALT 
n=130; abnormal ALT n=45), missing data was excluded to calculate the respective percent-
ages. 
Table V: Demographic factors, clinical findings and laboratory pa-
rameters between T2DM subjects with and without abnormal ALP
Variable
Normal ALP
(ALP 40 - 150 U/L)
n = 256 
Abnormal ALP
(ALP > 150 U/L)
n = 39 χ2* p
value***
n (%) n (%)
Gender 
Male
Female
132
124
(51.6)
(48.4)
22
17
(56.4)
(43.6)
0.319 0.572
Age (years)
< 60
≥ 60
121
135
(47.3)
(52.7)
25
14
(64.1)
(35.9)
3.838 0.050
Ethnicity 
Malay
Chinese
Indian
BMI****
Obese
Non Obese
142
62
52
50
70
(55.5)
(24.2)
(20.3)
(41.7)
(58.3)
23
9
7
8
13
(59.0)
(23.0)
(18.0)
(38.1)
(61.9)
   0.187
3.685
0.911
0.055
Duration T2DM**** 
(years) 
<5 
≥5 
44
104
(29.7)
(70.3)
8
15
(34.8)
(65.2)
0.013 0.910
Anti-diabetic med-
ication
OHA
Insulin
OHA & insulin
Statin
Yes
No
                     
143 
55 
58
      
 
   146 
110
(55.9)
(21.4)
(22.7)
(57.0)
(43.0)
16
18
5
25
14 
(41.0)
(46.2)
(12.8)
(64.1)
(35.9)
11.238
0.695
 0.004
0.405
Laboratory param-
eters
Medi-
an
(IQR) Median (IQR) z** p 
value***
FBG (mmol/L)  7.99 (6.74)   9.75 (7.45) -1.325 0.185
HbA1c (%)  8.00 (3.50)  8.00 (5.00)   -0.965 0.334
TC (mmol/L) 4.73 (1.82)  4.73 (2.79)  -1.116 0.265
TG (mmol/L)   1.64 (0.97)   1.88 (1.54)  -0.821 0.412
LDL (mmol/L)  2.80 (1.51)   2.86 (1.98)  -0.802 0.422
HDL mmol/L) 1.04 (0.39)  0.88 (0.51)  -2.752 0.006
Total protein (U/L)  73.0
                  
(8.00)        74.0 (11.0)  -0.175 0.861
ALB (g/L) 36.0 (7.00) 29.0 (11.0) -3.584 < 0.001
TBIL (µmol/L)  10.4 (7.20) 9.5 (12.4) -0.421 0.674
ALT (U/L)   19.0 (15.0) 22.0 (25.0) -2.493 0.013
*Since n > 20 and there is no expected value less than 5, Pearson Chi-Square is used. 
**Mann Whitney statistical test (z).
***Statistical significance at p < 0.05.  The significant variables are shown in bold. 
****For BMI (normal ALP n=120; abnormal ALP n=21) and duration of T2DM (normal ALP 
n=148; abnormal ALP n=23), missing data was excluded to calculate the respective percent-
ages.
Insulin resistance in T2DM is reflected by the chronic 
mild increase in transaminases. Similarly in this study, 
majority of patients had mild elevations of ALT and ALP. 
Considering that the ALT gene transcription is suppressed 
by insulin, the increase in ALT is hypothesised to be 
due to impaired insulin signaling rather than solely 
hepatocellular damage (4). High levels of liver ALP 
isoenzyme indicates cholestasis rather hepatocyte 
injury. Hepatosteatosis and insulin resistance in T2DM 
subjects may be responsible for ALP elevation (14). 
Our results showed that there was significant difference 
between normal and abnormal ALT with respect to 
age, BMI and duration of T2DM in study subjects. The 
percentage of subjects with abnormal ALT was higher in 
the age group less than 60 years old. Similar to previous 
research (24, 26, 27), this finding suggests that hepatic 
steatosis indicated by increased ALT levels in response 
to hepatocyte damage, tends to occur earlier in the 
course of the disease. In older patients, ALT, a biomarker 
of hepatocyte integrity declines as steatosis progresses 
while there is an inverse rise in AST level. Kamimoto et 
al attributed the rise in AST to the fact that because AST 
is mainly cleared by liver sinusoidal cells, advancing 
fibrosis injures these cells leading to the high levels (28). 
In this study, however, AST was not included as it is not 
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damage. 
Our study also found a significant association between 
normal and abnormal ALT groups with duration of 
T2DM. However, in the general study population as 
well as for both groups, higher percentage of subjects 
had T2DM for more than 5 years. This may be due to the 
fact that patients who are seen at the tertiary hospital are 
chronic diabetics and are only referred by the primary 
care physician when there is difficulty in glycaemic 
control and complications arise. Therapeutic lifestyle 
changes and early medical intervention are required to 
address the risk factors such as obesity, dyslipidaemia in 
younger diabetics to prevent progression of liver disease.
Although more than half the subjects were on treatment 
with OHA and/or statins, our results showed that 
the only significant association was for antidiabetic 
medication between T2DM patients with and without 
abnormal ALP. However, the type of OHA/statin was 
not documented, a limitation of this retrospective study. 
Metformin is a widely prescribed OHA and is the first-
line treatment for T2DM (31). Several studies have 
documented the anabolic effects of metformin on bone 
metabolism and its effect on increasing ALP, a bone 
formation marker (32, 33). Sulfonylureas, GLP-1 receptor 
agonist and insulin also promote bone formation (32). 
No significant association was found between abnormal 
liver enzymes and statin use in this study, concurring 
with the observations by Patra TK et al (3). 
Our study has several limitations. First, due to 
the retrospective nature of the study, some of the 
demographic factors, clinical findings and laboratory 
parameters were missing due to lack of recorded data. 
Most importantly, routine LFT was not done in all 
subjects. Only the results of the initial visit was extracted 
so the true details of the clinical condition may not be 
revealed. Hence, using only a single value of ALT and 
ALP as well as cut-off values, established from 2 standard 
deviations (SD) of respective enzyme estimations in 
apparently healthy subjects (laboratory reference range) 
to define derangement of liver enzymes may lead to 
underestimation of the burden of liver pathology in 
the population. Furthermore, being a cross-sectional 
study, temporal relationship could not be established 
as potential unmeasured confounders were not adjusted 
for. This leads to the question as to whether deranged 
liver enzymes preceded or followed some of the clinical 
and metabolic factors that were studied.
Further prospective studies should be carried out using 
a larger sample size involving other tertiary hospitals 
in Malaysia and including markers such as GGT, AST, 
adipokines, fasting insulin, HOMA-IR and ultrasound of 
the liver. These tests would help identify mechanisms 
behind abnormal liver enzymes in T2DM. Studies of 
interventions and therapeutic strategies for abnormal 
liver enzymes in T2DM subjects can also be done.
a routine investigation in the local LFT profile. 
Median BMI in our study population was 26.5 kg/m2, 
which is in the overweight range. Our finding of obese 
subjects (BMI > 30 kg/m2) having higher abnormal ALT 
compared to non-obese subjects is consistent with 
previous studies. Prevalence of raised ALT was higher 
among obese than non-obese diabetics with 10.6% 
and 6.6%, respectively in the US (19). Elevated ALT 
was significantly related to a BMI of > 25 kg/m2 among 
T2DM subjects in India (29). These findings substantiate 
the link between NAFLD and metabolic syndrome. 
Several constituents of metabolic syndrome such as 
insulin resistance, obesity, dyslipidaemia are also found 
in T2DM and are associated with NAFLD, suggesting 
that metabolic syndrome is a possible link between 
T2DM and NAFLD (6). Our study demonstrates 
statistically significant associations between the 
components of metabolic syndrome and raised ALT, 
which suggests that this can be used as a marker for 
NAFLD, albeit a non-specific one. Waist circumference 
to assess central obesity, which is a better parameter for 
metabolic syndrome was not measured (29). This can 
be considered as another limitation. However, we used 
BMI which is an accepted alternative to be a marker of 
metabolic syndrome (29). 
Whether NAFLD is related to the pathogenesis of T2DM 
or NAFLD is a contributing factor for the progression 
of T2DM is unclear. Majority of subjects in this study 
had long-standing DM with poor glycaemic control. 
However there was no significant association between 
enzyme groups with HbA1c, for both ALT and ALP. 
Manifestations of the metabolic syndrome, which often 
precedes T2DM, such as obesity, hyperinsulinemia, 
peripheral insulin resistance, hypertriglyceridaemia, 
and hypertension, have been previously suggested as 
a cause of NAFLD (29). This study is in keeping with 
the current understanding of the pathogenesis of NAFLD 
as a hepatic manifestation of the metabolic syndrome 
itself, as elevated ALT was commonly elevated in people 
with diagnosis of T2DM, suggesting that development of 
NAFLD may precede the diagnosis of T2DM.
Our data, demonstrating higher TG and lower HDL in the 
abnormal liver enzyme groups, support the hypothesis 
that the principal pathophysiology in NAFLD, is insulin 
resistance. Insulin resistance leads accumulation of 
hepatic TG by increased lipolysis, TG synthesis, and 
increased hepatic uptake of free fatty acids. Plasma HDL 
is decreased in T2DM related to increased catabolism of 
HDL particles due to hypertriglyceridaemia. The transfer 
of TG to HDL through cholesteryl ester transfer protein 
(CETP) leads to TG-rich HDLs formation. Hepatic lipase 
catabolises these HDLs (30). It has been demonstrated 
that HDLs from T2DM subjects have reduced anti-
oxidative and endothelium-dependent vasorelaxant 
properties (30), which may further contribute to liver 
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CONCLUSION
Our study on the crude prevalence of raised liver 
enzymes may help identify T2DM patients at increased 
risk of NAFLD. Modification of metabolic risk factors, 
such as weight loss, control of dyslipidaemia rather than 
just tighter glycaemic control should be emphasised in 
these patients to reduce morbidity and mortality. Liver 
enzymes remain a simple and non- invasive marker of 
liver pathology in daily medical practice.
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